www.ppscreeningcentre.com 
Pivot Park OssVan target tot markt 
25-Sep-2014 
Helma Rutjes
Contents 
•Pivot Park Life Sciences Community 
•Pivot Park Screening Centre 
•Organisatie 
•Mogelijkhedenvoorsamenwerkingen 
•ELF
Opening Oss Life Sciences Park 2012
Voornametrend in innovatieveentrepreneurship wereldwijd! 
Faciliterenvan open innovatie 
Pivot Park 
Gesloteninnovatie 
Open innovatie 
Van gesloten… 
•Solo-creatie 
•Transacties 
•IP legaldrive 
•Academischresearch middelsfondsenvanuitindustrie 
•Grote bedrijvenbepalenmarkttoegangvoorinnovatie 
… naaropen innovatie: 
•Co-creatie 
•Netwerk/Relationships 
•Entrepreneurial drive 
•Commerciele& Academischeresearch samenwerkingen 
•SMEs versnellenmarkttoegangin innovatie
Pivot Park OrganisatieChart 
ELF project management 
Screening 
manager 
Screening operations 
Assay development 
Assay Dev manager 
CSO 
CEO 
CFO 
COO 
CCO 
Business Development 
EHS management 
Facility management 
Account management
Pivot Park 
Analytics 
HTS 
uHTS 
Compounds 
Pilot Plant 
Animal 
facilities 
Lab & Office facilities 
Unique Facilities, Equipment, Knowledge and Approach 
•Fully equipped labs 
•Open Access labs 
•Flex labs 
•Nuclear Magnetic Resonance 
•Liquid Chromatography 
•Mass Spectrometry 
•Open Access HTS 
•Flexible uHTS 
•Hit / Lead optimization 
•Up to 10 kg 
•GMP standard 
•Small molecules 
•Hosted by BioXpert
Pivot Park Community (September 2014)
14-PPALG0055 
Pivot Park Community Interactome2013
Focus op vroegestadia medicijnontwikkeling 
Target ID 
Hit / Lead discovery 
Lead Optimization 
Pre clinical development 
Clinical phase I 
Clinical phase II 
Project management, Drug dev. Plan 
Suppliers: Pivot Park Based bedrijvenplus anderen 
Partners 
Preferred suppliers 
Top academenresearch partners 
High throughput 
Screening 
PPSC 
High content 
Screening 
NKI 
HubrechtInst 
Univ. Nijmegen 
Univ. Leiden 
Partner per indicatie 
BioXB.V. 
BioTB.V. 
Partners 
Core focus op ontwikkelingsfase
Pivot Park, 25 juni2014 
Pivot Park 2.0 concept
Pivot Park 2.0 
Uitbreiding faciliteiten: state-of-the-art pilot plant en laboratoriumfaciliteiten
Contents 
•Pivot Park Life Sciences Community 
•Pivot Park Screening Centre 
•Organisatie 
•Mogelijkhedenvoorsamenwerkingen 
•ELF
PPSC: Uw partner voor Screening 
30-9-2014 
Screening faciliteiten 
Automatiserings -en assay 
development specialisten 
Data processing 
Compounds
1995 
2000 
2005 
2010 
2015 
IntroductieMTS & HTS 
Biochemischeencellulairescreening 
ASPIRE: Geintegreerdin-vitro screening platform 
uHTS: capaciteit& miniaturisatie 
Sluitingresearch @ Oss 
NieuweSME 2012 
Systeemaanname& overdracht2012 
1stHTS in april2013 
Screening Historiein Oss
IndrukwekkendegroeibinnenPPSC 
0 
20 
40 
2012 
2013 
2014 
•Opening Pivot Park 
•Nieuwrobot systeem 
•2 fte 
•Volledigoperationeel 
•Start van ELF 
•18 fte 
•13 HTS 
•Uitbouwensamenwerkingen 
•HCA enFLIPR 
•18+ fte 
•30 HTS verwacht 
2012 
2013 
2014 
#HTS
ASPIRE systeem: Flexibeleautomatisering
State-of-the-art Equipment enWorkflows consistenteenhogekwaliteitdata
●19
MogelijkhedenbinnenPPSC 
•Assay ontwikkeling 
•Celkweek 
•Sample handling 
•Screening (Low, medium en high throughput) 
•Biochemische en cellulaire assays(High content) 
•Automatisering van in-vitroexperimenten 
•Optimalisatie en validatie van geautomatiseerde protocollen 
•Geautomatiseerde data processing 
30-9-2014 High Throughput Screening Facility
Velesamenwerkingengestart 
•Cancer Drug Discovery Initiative 
•NederlandsKankerInstituutenLeiden Universiteit 
•Gezamenlijkprogrammaom klinischekandidatenin oncologieteontwikkelen 
•Academischesamenwerkingenin Europa 
•C.elegansscreening/Horizon2020 aanvragen 
•Pivot Park bedrijven 
•NTRC screening projecten 
•Lab vooropen innovatie 
•Vroegeresearch samenwerkingenmet meerderebedrijven 
•European Lead Factory 
•30 partners, 7 EFPIA 
•120 HTS programma’sin 5 jaar
Disclaimer 
23 
Dear Reader, 
Only the official and formally signed contractual documents in relation to the EU Lead Factory (the Project Agreement, Grant Agreement, the Description of Work, and Third Party Access Agreements) have a binding value in relation to the subject matter covered in these slides. 
Any information contained in these slides is not binding upon the parties and can in no event be used to interpret or complement the formally signed contractual documents referred to above. 
The EU Lead Factory Team
Made Possible by 
24 
EU Lead Factory 
combines 
innovationof Academia, 
agility of SMEs, and 
experienceof Pharma 
and fundingfrom
Medicijnenonderzoekende waardeketen 
25 
Waardevan compound 
Target 
Hit finding 
Hit to lead 
Lead series 
Phase I & II 
Phase II & registrate 
Sales €€ 
Years 
3 
5 
6 
8 
11 
13 
25
A Large-Scale Controlled Experiment 
26 
Shared Useof Compound Collections 
Crowd- SourcingInnovation from Biology & Chemistry 
Partneringof Public Target Programmes 
Value Generation from Publicly- funded Initiative
Collaborative Drug Discovery 
27 
Molecular 
Targets 
European 
Screening 
Centre 
EFPIA contribution 
(>300.000 cpds) 
Public contribution 
(up to 200.000 cpds) 
Joint 
European 
Compound 
Library 
Compounds 
uHTS 
Compound logistics 
Hit triage 
Medicinal Chemistry
Target Programme Collaboration 
28 
EU Lead Factory Experts 
supporting and pavingthe way 
You 
in the lead 
Flying start 
drug discovery research
Assay development / uHTS 
29 
0 
2 
4 
6 
8 
10 
0 
1 
2 
3 
4 
5 
6 
0 
5 
10 
15 
384-wells 
1536-wells 
0 
5 
10 
15 
20 
biochemical 
cellular 
Number of platesscreened per day 
Technologiesprogrammes 
Plate format 
Assay typeprogrammes
Publieke Target Programma’s Voortgang 
30 
Submitted 
68 
Accepted 
31 
Assay 
development 
24 
uHTS 
14 
Hit 
Follow-up 
13 
QHL 
4 
Molecular 
Targets 
Sept 2014
www.ppscreeningcentre.com 
●31 
Eenmooietoekomst! 
30-9-2014 High Throughput Screening Facility 
•Oss herbergtHETEuropeseScreening Centrum 
•Europesefunding tot jan.2018 
•ELF is eeninnovatiefbusiness model voorPharma onderzoek 
•Samenwerkingin consortium leidttot nieuweopportunities
www.ppscreeningcentre.com 
●32 
Business Opportunity 
Pivot Park 
•Perfectelocatie, goedbereikbaar 
•Goedeatmosfeer: community 
•Starterspakketvoorlabinrichting 
•Van target tot markt 
•Van starter tot middelgrootbedrijf 
Pivot Park Screening Centre 
•Kwaliteit 
•Efficienteenvolledigeautomatisering 
•Flexibeleklant-georienteerdeservice 
•Samenwerkingen: improvement cycle 
•KansenvoorELF assays
www.ppscreeningcentre.com Molenstraat 110 • 5342 CC Oss • The Netherlands • +31 (0) 412 71 25 11 
Bedankt voor uw aandacht!

Smb 25092014 helma rutjes pivot park

  • 1.
    www.ppscreeningcentre.com Pivot ParkOssVan target tot markt 25-Sep-2014 Helma Rutjes
  • 2.
    Contents •Pivot ParkLife Sciences Community •Pivot Park Screening Centre •Organisatie •Mogelijkhedenvoorsamenwerkingen •ELF
  • 4.
    Opening Oss LifeSciences Park 2012
  • 5.
    Voornametrend in innovatieveentrepreneurshipwereldwijd! Faciliterenvan open innovatie Pivot Park Gesloteninnovatie Open innovatie Van gesloten… •Solo-creatie •Transacties •IP legaldrive •Academischresearch middelsfondsenvanuitindustrie •Grote bedrijvenbepalenmarkttoegangvoorinnovatie … naaropen innovatie: •Co-creatie •Netwerk/Relationships •Entrepreneurial drive •Commerciele& Academischeresearch samenwerkingen •SMEs versnellenmarkttoegangin innovatie
  • 6.
    Pivot Park OrganisatieChart ELF project management Screening manager Screening operations Assay development Assay Dev manager CSO CEO CFO COO CCO Business Development EHS management Facility management Account management
  • 7.
    Pivot Park Analytics HTS uHTS Compounds Pilot Plant Animal facilities Lab & Office facilities Unique Facilities, Equipment, Knowledge and Approach •Fully equipped labs •Open Access labs •Flex labs •Nuclear Magnetic Resonance •Liquid Chromatography •Mass Spectrometry •Open Access HTS •Flexible uHTS •Hit / Lead optimization •Up to 10 kg •GMP standard •Small molecules •Hosted by BioXpert
  • 8.
    Pivot Park Community(September 2014)
  • 9.
    14-PPALG0055 Pivot ParkCommunity Interactome2013
  • 10.
    Focus op vroegestadiamedicijnontwikkeling Target ID Hit / Lead discovery Lead Optimization Pre clinical development Clinical phase I Clinical phase II Project management, Drug dev. Plan Suppliers: Pivot Park Based bedrijvenplus anderen Partners Preferred suppliers Top academenresearch partners High throughput Screening PPSC High content Screening NKI HubrechtInst Univ. Nijmegen Univ. Leiden Partner per indicatie BioXB.V. BioTB.V. Partners Core focus op ontwikkelingsfase
  • 11.
    Pivot Park, 25juni2014 Pivot Park 2.0 concept
  • 12.
    Pivot Park 2.0 Uitbreiding faciliteiten: state-of-the-art pilot plant en laboratoriumfaciliteiten
  • 13.
    Contents •Pivot ParkLife Sciences Community •Pivot Park Screening Centre •Organisatie •Mogelijkhedenvoorsamenwerkingen •ELF
  • 14.
    PPSC: Uw partnervoor Screening 30-9-2014 Screening faciliteiten Automatiserings -en assay development specialisten Data processing Compounds
  • 15.
    1995 2000 2005 2010 2015 IntroductieMTS & HTS Biochemischeencellulairescreening ASPIRE: Geintegreerdin-vitro screening platform uHTS: capaciteit& miniaturisatie Sluitingresearch @ Oss NieuweSME 2012 Systeemaanname& overdracht2012 1stHTS in april2013 Screening Historiein Oss
  • 16.
    IndrukwekkendegroeibinnenPPSC 0 20 40 2012 2013 2014 •Opening Pivot Park •Nieuwrobot systeem •2 fte •Volledigoperationeel •Start van ELF •18 fte •13 HTS •Uitbouwensamenwerkingen •HCA enFLIPR •18+ fte •30 HTS verwacht 2012 2013 2014 #HTS
  • 17.
  • 18.
    State-of-the-art Equipment enWorkflowsconsistenteenhogekwaliteitdata
  • 19.
  • 20.
    MogelijkhedenbinnenPPSC •Assay ontwikkeling •Celkweek •Sample handling •Screening (Low, medium en high throughput) •Biochemische en cellulaire assays(High content) •Automatisering van in-vitroexperimenten •Optimalisatie en validatie van geautomatiseerde protocollen •Geautomatiseerde data processing 30-9-2014 High Throughput Screening Facility
  • 21.
    Velesamenwerkingengestart •Cancer DrugDiscovery Initiative •NederlandsKankerInstituutenLeiden Universiteit •Gezamenlijkprogrammaom klinischekandidatenin oncologieteontwikkelen •Academischesamenwerkingenin Europa •C.elegansscreening/Horizon2020 aanvragen •Pivot Park bedrijven •NTRC screening projecten •Lab vooropen innovatie •Vroegeresearch samenwerkingenmet meerderebedrijven •European Lead Factory •30 partners, 7 EFPIA •120 HTS programma’sin 5 jaar
  • 23.
    Disclaimer 23 DearReader, Only the official and formally signed contractual documents in relation to the EU Lead Factory (the Project Agreement, Grant Agreement, the Description of Work, and Third Party Access Agreements) have a binding value in relation to the subject matter covered in these slides. Any information contained in these slides is not binding upon the parties and can in no event be used to interpret or complement the formally signed contractual documents referred to above. The EU Lead Factory Team
  • 24.
    Made Possible by 24 EU Lead Factory combines innovationof Academia, agility of SMEs, and experienceof Pharma and fundingfrom
  • 25.
    Medicijnenonderzoekende waardeketen 25 Waardevan compound Target Hit finding Hit to lead Lead series Phase I & II Phase II & registrate Sales €€ Years 3 5 6 8 11 13 25
  • 26.
    A Large-Scale ControlledExperiment 26 Shared Useof Compound Collections Crowd- SourcingInnovation from Biology & Chemistry Partneringof Public Target Programmes Value Generation from Publicly- funded Initiative
  • 27.
    Collaborative Drug Discovery 27 Molecular Targets European Screening Centre EFPIA contribution (>300.000 cpds) Public contribution (up to 200.000 cpds) Joint European Compound Library Compounds uHTS Compound logistics Hit triage Medicinal Chemistry
  • 28.
    Target Programme Collaboration 28 EU Lead Factory Experts supporting and pavingthe way You in the lead Flying start drug discovery research
  • 29.
    Assay development /uHTS 29 0 2 4 6 8 10 0 1 2 3 4 5 6 0 5 10 15 384-wells 1536-wells 0 5 10 15 20 biochemical cellular Number of platesscreened per day Technologiesprogrammes Plate format Assay typeprogrammes
  • 30.
    Publieke Target Programma’sVoortgang 30 Submitted 68 Accepted 31 Assay development 24 uHTS 14 Hit Follow-up 13 QHL 4 Molecular Targets Sept 2014
  • 31.
    www.ppscreeningcentre.com ●31 Eenmooietoekomst! 30-9-2014 High Throughput Screening Facility •Oss herbergtHETEuropeseScreening Centrum •Europesefunding tot jan.2018 •ELF is eeninnovatiefbusiness model voorPharma onderzoek •Samenwerkingin consortium leidttot nieuweopportunities
  • 32.
    www.ppscreeningcentre.com ●32 BusinessOpportunity Pivot Park •Perfectelocatie, goedbereikbaar •Goedeatmosfeer: community •Starterspakketvoorlabinrichting •Van target tot markt •Van starter tot middelgrootbedrijf Pivot Park Screening Centre •Kwaliteit •Efficienteenvolledigeautomatisering •Flexibeleklant-georienteerdeservice •Samenwerkingen: improvement cycle •KansenvoorELF assays
  • 33.
    www.ppscreeningcentre.com Molenstraat 110• 5342 CC Oss • The Netherlands • +31 (0) 412 71 25 11 Bedankt voor uw aandacht!